Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty ...

Nonalcoholic fatty liver disease (NAFLD) is very common; as many as 25 percent of adults around the world are impacted by the disorder. In NAFLD, liver cells die, damaging the organ. NALFD can also ...

Biotech company 89bio said Wednesday that its experimental treatment improved liver scarring at more than three times the rate of placebo without worsening other symptoms of patients with the fatty ...

NASH affects 1.5%-6.5% of U.S. adults, with no FDA-approved treatments, but lifestyle changes are recommended. ICER is evaluating resmetirom and obeticholic acid (OCA) for NASH, focusing on clinical ...

Please provide your email address to receive an email when new articles are posted on . Gastroenterologists and hepatologists were leaders in nonalcoholic steatohepatitis diagnosis and viewed as ...